By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

Millennium Pharmaceuticals Inc. et al. v. Teva Parenteral Medicines Inc. et al.
1:09-cv-00105; filed February 18, 2009 in the District Court of Delaware

Infringement of U.S. Patent No. 5,807,825 ("Platelet Aggregation Inhibitors," issued September 15, 1998), licensed to Schering Corp., following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Schering-Plough's Integrilin® (eptifibatide injection, used to treat acute coronary syndrome).  View the complaint here.

Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo v. Doll
1:09-cv-00308; filed February 17, 2009 in the District Court of the District of Columbia

Review and correction of the patent term adjustment calculation made by the USPTO for U.S. Patent No. 7,414,038 ("Embolic Materials," issued August 19, 2008).  View the complaint here.

Phylonix Pharmaceuticals, Inc. v. Zygogen, LLC
1:09-cv-10220; filed February 13, 2009 in the District Court of Massachusetts

Infringement of U.S. Patent Nos. 6,656,449 ("Methods of Screening Agents For Activity Using Teleosts," issued December 2, 2003), 7,041,276 (same title, issued May 9, 2006), and 7,482,507 (same title, issued January 27, 2009) based on Zygogen's manufacture and sale of its Z-Tag Angiogenesis Assay and related compound screening services.  View the complaint here.

Intema Ltd. v. NTD Laboratories, Inc. et al.
2:09-cv-00633; filed February 13, 2009 in the Eastern District of New York

Infringement of U.S. Patent No. 6,573,103 ("Antenatal Screening for Down's Syndrome," issued June 3, 2003) based on Perkin Elmer's marketing of its Modified Sequential Screening protocol.  View the complaint here.

Astrazeneca Pharmaceuticals LP et al. v. Accord Healthcare, Inc. et al.
3:09-cv-00619; filed February 10, 2009 in the District Court of New Jersey

Infringement of U.S. Patent Nos. 4,879,288 ("Novel Dibenzothiazepine Antipsychotic," issued November 7, 1989) and 5,948,437 ("Pharmaceutical Compositions Using Thiazepine," issued September 7, 1999) following a Paragraph IV certification as part of Accord's filing of an amendment to its ANDA (adding additional dosage forms) to manufacture a generic version of AstraZeneca's Seroquel® XR (quetiapine fumarate, used to treat schizophrenia and bipolar disorder).  View the complaint here.